AIM ImmunoTech (AIM) announces NYSE delisting, plans to appeal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
April 4, 2025 4:45 PM EDTOCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (AIM or the Company) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the NYSE American or the Exchange) that it had suspended trading of the Companys common stock and of its determination to commence delisting proceedings of the Companys common stock from the Exchange pursuant to Section 1003(f)(v) of the... More
